China SXT Pharmaceuticals (SXTC) Current Assets (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Current Assets for 9 consecutive years, with $34.5 million the latest figure, recorded in Q1 2026.

• Quarterly Current Assets rose 62.04% year-over-year to $34.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.5 million (up 62.04% YoY) and the FY2026 annual result came in at $34.5 million, up 62.04% from the prior year.
• Current Assets advanced to $34.5 million in Q1 2026 per SXTC's latest filing, from $26.0 million in the prior quarter.
• Over the last five years, Current Assets for SXTC reached as high as $34.5 million in Q1 2026 and fell as low as $12.4 million in Q3 2022.
• A 5-year average of $20.7 million and a median of $21.3 million in 2025 frame the typical range for Current Assets.
• The largest YoY upside for Current Assets was 62.93% in 2024 against a maximum downside of 27.09% in 2024.
• Year by year, Current Assets stood at $12.4 million in 2022, then rose by 9.19% to $13.5 million in 2023, then jumped by 62.93% to $22.0 million in 2024, then climbed by 18.44% to $26.0 million in 2025, then jumped by 32.51% to $34.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $34.5 million, $26.0 million, and $21.3 million for Q1 2026, Q3 2025, and Q1 2025 respectively.